Incanthera ^Companies

Incanthera Ltd. develops cancer treatment drugs. Its ICT-2588 is a lead compound that is activated within solid tumours by a specific matrix metalloprotease enzyme. The company was incorporated in 2010 and is based in Liverpool, United Kingdom.